These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 7597122)

  • 1. Extrapyramidal side effects of clozapine and haloperidol.
    Kurz M; Hummer M; Oberbauer H; Fleischhacker WW
    Psychopharmacology (Berl); 1995 Mar; 118(1):52-6. PubMed ID: 7597122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute Extrapyramidal Side Effects Associated With the Combined Use of Low Doses of Haloperidol and Clarithromycin.
    Gunes S; Inal Ulutas G; Sefik P; Ozluk HK; Tanrikulu EE
    Cureus; 2023 Dec; 15(12):e51020. PubMed ID: 38264367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extrapyramidal symptoms during long-term treatment with antipsychotics: special focus on clozapine and D1 and D2 dopamine antagonists.
    Gerlach J; Lublin H; Peacock L
    Neuropsychopharmacology; 1996 Mar; 14(3 Suppl):35S-39S. PubMed ID: 8866742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clozapine, negative symptoms, and extrapyramidal side effects.
    Kane JM; Safferman AZ; Pollack S; Johns C; Szymanski S; Kronig M; Lieberman JA
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():74-7. PubMed ID: 7961579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics.
    Miller CH; Mohr F; Umbricht D; Woerner M; Fleischhacker WW; Lieberman JA
    J Clin Psychiatry; 1998 Feb; 59(2):69-75. PubMed ID: 9501888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic/mammalian target of rapamycin and side effects of antipsychotics: insights into mechanisms and implications for therapy.
    Zhuo C; Xu Y; Hou W; Chen J; Li Q; Liu Z; Dou G; Sun Y; Li R; Ma X; Tian H; Zhou C
    Transl Psychiatry; 2022 Jan; 12(1):13. PubMed ID: 35013125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Understanding of the Neurobiology of Agitation.
    Miller CWT; Hodzic V; Weintraub E
    West J Emerg Med; 2020 Jul; 21(4):841-848. PubMed ID: 32726254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety Assessment of Liver Injury with Quetiapine Fumarate XR Management in Very Heavy Drinking Alcohol-Dependent Patients.
    Vatsalya V; Pandey A; Schwandt ML; Cave MC; Barve SS; Ramchandani VA; McClain CJ
    Clin Drug Investig; 2016 Nov; 36(11):935-944. PubMed ID: 27503091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future.
    Li P; Snyder GL; Vanover KE
    Curr Top Med Chem; 2016; 16(29):3385-3403. PubMed ID: 27291902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic Islet Responses to Metabolic Trauma.
    Burke SJ; Karlstad MD; Collier JJ
    Shock; 2016 Sep; 46(3):230-8. PubMed ID: 26974425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation.
    Hackler EA; Byun NE; Jones CK; Williams JM; Baheza R; Sengupta S; Grier MD; Avison M; Conn PJ; Gore JC
    Neuroscience; 2010 Jun; 168(1):209-18. PubMed ID: 20350588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clozapine versus typical neuroleptic medication for schizophrenia.
    Essali A; Al-Haj Haasan N; Li C; Rathbone J
    Cochrane Database Syst Rev; 2009 Jan; 2009(1):CD000059. PubMed ID: 19160174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Movement disorders: neurodevelopment and neurobehavioural expression.
    Archer T; Beninger RJ
    J Neural Transm (Vienna); 2007; 114(4):XXXIII-XLI. PubMed ID: 17024325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching between second-generation antipsychotics: why and how?
    Edlinger M; Baumgartner S; Eltanaihi-Furtmüller N; Hummer M; Fleischhacker WW
    CNS Drugs; 2005; 19(1):27-42. PubMed ID: 15651903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second generation antipsychotics.
    Fleischhacker WW
    Psychopharmacology (Berl); 2002 Jun; 162(1):90-1. PubMed ID: 12141274
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.
    Stip E
    J Psychiatry Neurosci; 2000 Mar; 25(2):137-53. PubMed ID: 10740987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes.
    Fleischhacker WW; Hummer M
    Drugs; 1997 Jun; 53(6):915-29. PubMed ID: 9179524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-induced movement disorders.
    Jiménez-Jiménez FJ; García-Ruiz PJ; Molina JA
    Drug Saf; 1997 Mar; 16(3):180-204. PubMed ID: 9098656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects.
    Peacock L; Solgaard T; Lublin H; Gerlach J
    Psychopharmacology (Berl); 1996 Mar; 124(1-2):188-96. PubMed ID: 8935815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral effects of sertindole, risperidone, clozapine and haloperidol in Cebus monkeys.
    Casey DE
    Psychopharmacology (Berl); 1996 Mar; 124(1-2):134-40. PubMed ID: 8935808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.